Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRCA1 expression and Doxil response in metastatic breast cancer
NCT01990352Phase 2Terminated
- Sponsor
- University of Arizona
- Start
- Nov 2013
- Primary completion
- Dec 2022
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin in breast cancer, sponsored by University of Arizona. Started Nov 2013; status: terminated.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01990352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01990352.